

Ask more questions to explore your options

Your questions are important—and you should always discuss them with your healthcare team

Before your or your loved one's next doctor appointment, download this guide to help you prepare for your conversation. You can use the space beneath each question and on page 3 to take notes.

What is BRAFTOVI + MEKTOVI?

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) are prescription medicines used together to treat adults with a type of skin cancer called melanoma:

- that has spread to other parts of the body or cannot be removed by surgery, **and**
- that has a certain type of abnormal "BRAF" gene

BRAFTOVI should not be used to treat people with wild-type BRAF melanoma. Your healthcare provider will perform a test to make sure that BRAFTOVI + MEKTOVI is right for you.

It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.

Questions about this diagnosis

What does it mean that my melanoma is "metastatic"?

What does it mean when my doctor says my melanoma is "unresectable"?

What are biomarkers? Should biomarker testing be done?

Would testing positive for the BRAF (V600E or V600K) biomarker help identify appropriate treatment options for me?

Selected Important Safety Information

BRAFTOVI and MEKTOVI may cause serious side effects, including risk of new skin cancers. Check your skin and tell your healthcare provider right away about any skin changes, including a: new wart; skin sore or reddish bump that bleeds or does not heal; change in size or color of a mole.

Please see additional Important Safety Information on pages 4-6 and both BRAFTOVI full [Prescribing Information](#), including [Medication Guide](#), and MEKTOVI full [Prescribing Information](#), including [Medication Guide](#), for additional information.



Questions about starting treatment with BRAFTOVI + MEKTOVI

Would a BRAF targeted therapy be right for my type of melanoma?

Is BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) a treatment option based on my diagnosis?

How does BRAFTOVI + MEKTOVI work?

Questions about taking BRAFTOVI + MEKTOVI

What information should I know about taking BRAFTOVI + MEKTOVI?

Can I take BRAFTOVI + MEKTOVI with or without meals?

What should I do if I miss a dose of BRAFTOVI or MEKTOVI?

What do I need to know about the possible serious side effects of BRAFTOVI + MEKTOVI?
What are the common side effects of this treatment combination?

Will my insurance cover BRAFTOVI + MEKTOVI? Are there additional financial support options?

Selected Important Safety Information

BRAFTOVI and MEKTOVI may cause serious side effects, including heart problems or heart failure. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing; shortness of breath; swelling in your hands, ankles, legs, or feet; feeling faint or light-headed.

Please see additional Important Safety Information on pages 4-6 and both BRAFTOVI full [Prescribing Information](#), including [Medication Guide](#), and MEKTOVI full [Prescribing Information](#), including [Medication Guide](#), for additional information.



My notes

You can use this page before or during your next doctor appointment to write down notes, questions, or any other things to remember.

Pfizer Oncology together™

Turn to Pfizer Oncology Together for financial assistance resources and personalized support.



CALL **1-877-744-5675**
(Monday–Friday 8 AM–8 PM ET)

VISIT PfizerOncologyTogether.com

Important Safety Information and Indication

What is the most important information I should know about BRAFTOVI (encorafenib) and MEKTOVI (binimetinib)?

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) may cause serious side effects, including:

- **Risk of new skin cancers.** BRAFTOVI or BRAFTOVI when used with MEKTOVI can cause skin cancers called cutaneous squamous cell carcinoma or basal cell carcinoma. Talk to your healthcare provider about your risk for these cancers.

Check your skin and tell your healthcare provider right away about any skin changes, including a:
 - new wart
 - skin sore or reddish bump that bleeds or does not heal
 - change in size or color of a moleYour healthcare provider should check your skin before treatment, every 2 months during treatment, and for up to 6 months after you stop treatment to look for any new skin cancers.

Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that develop during treatment.
- **Heart problems, including heart failure.** BRAFTOVI or MEKTOVI taken with BRAFTOVI can cause heart problems. Your healthcare provider will check your heart function before and during treatment. Tell your healthcare provider right away if you have any of the following signs and symptoms of a heart problem:
 - feeling like your heart is pounding or racing
 - shortness of breath
 - swelling in your hands, ankles, legs, or feet
 - feeling faint or light-headed

- **Liver problems.** BRAFTOVI or MEKTOVI taken with BRAFTOVI can cause liver problems. Your healthcare provider will perform blood tests to check your liver function before and during treatment. Tell your healthcare provider if you have any of the following signs and symptoms of a liver problem:
 - yellowing of your skin or your eyes
 - dark or brown (tea-colored) urine
 - nausea or vomiting
 - loss of appetite
 - tiredness
 - bruising
 - bleeding
- **Muscle problems (rhabdomyolysis).** MEKTOVI, when taken with BRAFTOVI, can cause muscle problems that can be severe. MEKTOVI may increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Your healthcare provider should perform a blood test to check your CPK levels before and during treatment. Tell your healthcare provider right away if you develop any of these symptoms:
 - weakness
 - muscle aches or pain
 - dark, reddish urine
- **Bleeding problems.** BRAFTOVI or MEKTOVI taken with BRAFTOVI can cause serious bleeding problems, including in your stomach or brain, that can lead to death. Tell your healthcare provider and get medical help right away if you develop any signs of bleeding, including:
 - headaches, dizziness, or feeling weak
 - cough up blood or blood clots
 - vomit blood or your vomit looks like "coffee grounds"
 - red or black stools that look like tar
 - nose bleeds

Please see additional Important Safety Information on pages 5-6 and both BRAFTOVI full Prescribing Information, including Medication Guide, and MEKTOVI full Prescribing Information, including Medication Guide, for additional information.



Important Safety Information and Indication (continued)

- **Blood clots.** MEKTOVI, when taken with BRAFTOVI (encorafenib), can cause blood clots in your arms or legs, which can travel to your lungs and can lead to death. Get medical help right away if you have the following symptoms:
 - chest pain
 - sudden shortness of breath or trouble breathing
 - pain in your legs with or without swelling
 - swelling in your arms and legs
 - a cool, pale arm or leg
- **Eye problems.** BRAFTOVI or MEKTOVI taken with BRAFTOVI can cause eye problems. Your healthcare provider should perform an eye exam regularly during treatment. Tell your healthcare provider right away if you develop any new or worsening symptoms of eye problems, including:
 - blurred vision, loss of vision, or other vision changes
 - see colored dots
 - see halos (blurred outline around objects)
 - eye pain, swelling, or redness
- **Changes in the electrical activity of your heart called QT prolongation.** QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider should do tests before you start taking BRAFTOVI and during your treatment to check your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, light-headed, dizzy, or if you feel your heart beating irregularly or fast during treatment with BRAFTOVI. These symptoms may be related to QT prolongation

- **Lung or breathing problems.** MEKTOVI, when taken with BRAFTOVI, can cause lung or breathing problems. Tell your healthcare provider if you have any new or worsening symptoms of lung or breathing problems, including:

- shortness of breath
- cough

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with BRAFTOVI and MEKTOVI if you have certain side effects.

Tell your healthcare team if you are pregnant or plan to become pregnant. BRAFTOVI and MEKTOVI can harm your unborn baby.

Females who are able to become pregnant:

- Should use effective nonhormonal birth control (contraception) during and for at least:
 - 2 weeks after the last dose of BRAFTOVI
 - 30 days after the last dose of MEKTOVI
- Birth control methods that contain hormones (such as birth control pills, injections, or transdermal systems) may not work as well during treatment with BRAFTOVI
- Your healthcare provider will do a pregnancy test before you start taking BRAFTOVI and MEKTOVI. Tell your healthcare provider right away if you become pregnant or think you might become pregnant during treatment

Talk to your healthcare team if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment with BRAFTOVI and MEKTOVI and for:

- 2 weeks after the last dose of BRAFTOVI
- 3 days after the last dose of MEKTOVI

Please see additional Important Safety Information on pages 4 and 6 and both BRAFTOVI full Prescribing Information, including Medication Guide, and MEKTOVI full Prescribing Information, including Medication Guide, for additional information.



Important Safety Information and Indication (continued)

BRAFTOVI (encorafenib) may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you.

The most common side effects of BRAFTOVI when taken with MEKTOVI (binimetinib) include: fatigue, nausea, vomiting, stomach-area (abdominal) pain, pain or swelling of your joints (arthralgia), and diarrhea.

Before taking BRAFTOVI + MEKTOVI, tell your healthcare provider about all of your medical conditions, including if you:

- have or have had bleeding problems
- have eye problems
- have heart problems, including a condition called long QT syndrome
- have been told that you have low blood levels of potassium, calcium, or magnesium
- have liver or kidney problems
- have had blood clots
- have lung or breathing problems
- have any muscle problems
- have high blood pressure (hypertension)
- are pregnant or plan to become pregnant. BRAFTOVI and MEKTOVI can harm your unborn baby
- are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. BRAFTOVI and certain other medicines can affect each other, causing side effects or affecting how BRAFTOVI or other medicines work. You should also avoid grapefruit products during treatment with BRAFTOVI.

These are not all of the possible side effects of BRAFTOVI and MEKTOVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at **1-800-FDA-1088** or visit www.fda.gov/medwatch. You may also report side effects to Pfizer Inc. at **1-800-438-1985**.

What is BRAFTOVI (encorafenib) + MEKTOVI (binimetinib)?

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) are prescription medicines used together to treat adults with a type of skin cancer called melanoma:

- that has spread to other parts of the body or cannot be removed by surgery, **and**
- that has a certain type of abnormal “BRAF” gene

BRAFTOVI should not be used to treat people with wild-type BRAF melanoma. Your healthcare provider will perform a test to make sure that BRAFTOVI + MEKTOVI is right for you.

It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.

Please see additional Important Safety Information on pages 4-5 and both BRAFTOVI full [Prescribing Information](#), including [Medication Guide](#), and MEKTOVI full [Prescribing Information](#), including [Medication Guide](#), for additional information.

